Cargando…

Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness

BACKGROUND: There is a paucity of information on coronavirus disease 2019 (COVID-19) outcomes in asthmatics. OBJECTIVE: To identify risk factors associated with admission and subsequent mortality among COVID-19–infected asthmatics. METHODS: Adults at our institution with a positive polymerase chain...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferastraoaru, Denisa, Hudes, Golda, Jerschow, Elina, Jariwala, Sunit, Karagic, Merhunisa, de Vos, Gabriele, Rosenstreich, David, Ramesh, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826039/
https://www.ncbi.nlm.nih.gov/pubmed/33495097
http://dx.doi.org/10.1016/j.jaip.2020.12.045
_version_ 1783640447121358848
author Ferastraoaru, Denisa
Hudes, Golda
Jerschow, Elina
Jariwala, Sunit
Karagic, Merhunisa
de Vos, Gabriele
Rosenstreich, David
Ramesh, Manish
author_facet Ferastraoaru, Denisa
Hudes, Golda
Jerschow, Elina
Jariwala, Sunit
Karagic, Merhunisa
de Vos, Gabriele
Rosenstreich, David
Ramesh, Manish
author_sort Ferastraoaru, Denisa
collection PubMed
description BACKGROUND: There is a paucity of information on coronavirus disease 2019 (COVID-19) outcomes in asthmatics. OBJECTIVE: To identify risk factors associated with admission and subsequent mortality among COVID-19–infected asthmatics. METHODS: Adults at our institution with a positive polymerase chain reaction for COVID-19 between March 14 and April 27, 2020, were retrospectively identified. Comorbidities, laboratory results, and mortality rates during hospitalization were recorded. RESULTS: In total, 737 of 951 (77.5%) asthma patients with COVID-19 were seen in the emergency department (ED), and 78.8% of these ED patients (581 of 737) were admitted. Individuals with previously measured mean absolute eosinophil counts (AEC) ≥150 cells/μL were less likely to be admitted (odds ratio [OR] = 0.46, 95% confidence interval [CI]: 0.21-0.98, P = .04), whereas concomitant heart failure (CHF), chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD) were risk factors for admission. Hospitalized patients with asthma with peak hospital-measured AEC ≥150 cells/μL (n = 104) were less likely to die compared with those whose AEC remained <150 cells/μL (n = 213) (mortality rate 9.6% vs 25.8%; OR = 0.006, 95% CI: 0.0001-0.64, P = .03). This group had also higher preadmission mean AEC (237 ± 181 vs 163 ± 147 cells/μL, P = .001, OR = 2012, 95% CI: 27.3-14,816). The mortality rate in patients with asthma alone (no associated CHF, CKD, COPD, diabetes, or hypertension) was similar to that of patients without asthma or any of these comorbidities. CONCLUSIONS: In asthmatics, pre-existing eosinophilia (AEC ≥150 cells/μL) was protective from COVID-19–associated admission, and development of eosinophilia (AEC ≥150 cells/μL) during hospitalization was associated with decreased mortality. Preadmission AEC influenced the AEC trend during hospitalization. Having a Th2-asthma phenotype might be an important predictor for reduced COVID-19 morbidity and mortality that should be further explored in prospective and mechanistic studies.
format Online
Article
Text
id pubmed-7826039
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Academy of Allergy, Asthma & Immunology
record_format MEDLINE/PubMed
spelling pubmed-78260392021-01-25 Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness Ferastraoaru, Denisa Hudes, Golda Jerschow, Elina Jariwala, Sunit Karagic, Merhunisa de Vos, Gabriele Rosenstreich, David Ramesh, Manish J Allergy Clin Immunol Pract Original Article BACKGROUND: There is a paucity of information on coronavirus disease 2019 (COVID-19) outcomes in asthmatics. OBJECTIVE: To identify risk factors associated with admission and subsequent mortality among COVID-19–infected asthmatics. METHODS: Adults at our institution with a positive polymerase chain reaction for COVID-19 between March 14 and April 27, 2020, were retrospectively identified. Comorbidities, laboratory results, and mortality rates during hospitalization were recorded. RESULTS: In total, 737 of 951 (77.5%) asthma patients with COVID-19 were seen in the emergency department (ED), and 78.8% of these ED patients (581 of 737) were admitted. Individuals with previously measured mean absolute eosinophil counts (AEC) ≥150 cells/μL were less likely to be admitted (odds ratio [OR] = 0.46, 95% confidence interval [CI]: 0.21-0.98, P = .04), whereas concomitant heart failure (CHF), chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD) were risk factors for admission. Hospitalized patients with asthma with peak hospital-measured AEC ≥150 cells/μL (n = 104) were less likely to die compared with those whose AEC remained <150 cells/μL (n = 213) (mortality rate 9.6% vs 25.8%; OR = 0.006, 95% CI: 0.0001-0.64, P = .03). This group had also higher preadmission mean AEC (237 ± 181 vs 163 ± 147 cells/μL, P = .001, OR = 2012, 95% CI: 27.3-14,816). The mortality rate in patients with asthma alone (no associated CHF, CKD, COPD, diabetes, or hypertension) was similar to that of patients without asthma or any of these comorbidities. CONCLUSIONS: In asthmatics, pre-existing eosinophilia (AEC ≥150 cells/μL) was protective from COVID-19–associated admission, and development of eosinophilia (AEC ≥150 cells/μL) during hospitalization was associated with decreased mortality. Preadmission AEC influenced the AEC trend during hospitalization. Having a Th2-asthma phenotype might be an important predictor for reduced COVID-19 morbidity and mortality that should be further explored in prospective and mechanistic studies. American Academy of Allergy, Asthma & Immunology 2021-03 2021-01-23 /pmc/articles/PMC7826039/ /pubmed/33495097 http://dx.doi.org/10.1016/j.jaip.2020.12.045 Text en © 2020 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Ferastraoaru, Denisa
Hudes, Golda
Jerschow, Elina
Jariwala, Sunit
Karagic, Merhunisa
de Vos, Gabriele
Rosenstreich, David
Ramesh, Manish
Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness
title Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness
title_full Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness
title_fullStr Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness
title_full_unstemmed Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness
title_short Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness
title_sort eosinophilia in asthma patients is protective against severe covid-19 illness
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826039/
https://www.ncbi.nlm.nih.gov/pubmed/33495097
http://dx.doi.org/10.1016/j.jaip.2020.12.045
work_keys_str_mv AT ferastraoarudenisa eosinophiliainasthmapatientsisprotectiveagainstseverecovid19illness
AT hudesgolda eosinophiliainasthmapatientsisprotectiveagainstseverecovid19illness
AT jerschowelina eosinophiliainasthmapatientsisprotectiveagainstseverecovid19illness
AT jariwalasunit eosinophiliainasthmapatientsisprotectiveagainstseverecovid19illness
AT karagicmerhunisa eosinophiliainasthmapatientsisprotectiveagainstseverecovid19illness
AT devosgabriele eosinophiliainasthmapatientsisprotectiveagainstseverecovid19illness
AT rosenstreichdavid eosinophiliainasthmapatientsisprotectiveagainstseverecovid19illness
AT rameshmanish eosinophiliainasthmapatientsisprotectiveagainstseverecovid19illness